An open label, repeat dose, dose escalation study conducted in Parkinson's disease patients to characterize the pharmacokinetics and effect of food on ropinirole prolonged release (PR/CR [controlled release]) 12mg tablets
Phase of Trial: Phase II
Latest Information Update: 03 Nov 2016
At a glance
- Drugs Ropinirole (Primary)
- Indications Parkinson's disease
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline
- 08 Nov 2007 Status changed from initiated to completed.
- 21 Jun 2007 New trial record.